Savolitinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Savolitinib
Savolitinib.svg
Clinical data
SynonymsVolitinib
Identifiers
CAS Number
ChemSpider
KEGG
Chemical and physical data
FormulaC17H15N9
Molar mass345.37 g·mol−1
3D model (JSmol)

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2]

References[edit]